The ubiquitin-proteasome system (UPS) modulates the ubiquitination and degradation of many proteins and thus alters their abundance and biological functions. The core clock protein, aryl hydrocarbon receptor nuclear translocator-like protein 1 (ARNTL or BMAL1), is the master regulator of the circadian clock and plays important roles in the regulation of many biological processes, such as protein synthesis, cell senescence, and circadian rhythms. However, the influence of the UPS on BMAL1 is not fully understood. Here, we find an E3 ubiquitin ligase, TNF receptor-associated factor 2 (TRAF2), as an interacting protein of BMAL1 to reduce its stability. Biochemical experiments demonstrate that this regulation is achieved through the ubiquitination and subsequent degradation of BMAL1. We further reveal that BMAL1 preferentially interacts with the zinc finger domain but not the conventional substrate recognition domain in TRAF2. Functional studies find that TRAF2 expression reduces the BMAL1 transcriptional activity and Traf2 knockdown elevates the maximal Per1 mRNA level of the circadian clock in a neuroblastoma cell line. This work discovers TRAF2 as a novel regulatory factor for BMAL1 and reveals a new domain in TRAF2 for substrate binding, which may extend the regulatory functions of TRAF2 and BMAL1 in many biological processes, such as circadian rhythm.
Introduction
The circadian clock maintains an approximately 24-h day-night cycle in living organisms on the earth [1] . The central circadian clock is regulated by a core transcription-translation feedback loop (TTFL) [2, 3] . The positive limb of this feedback loop consists of two core clock proteins, circadian locomoter output cycles protein kaput (CLOCK) and aryl hydrocarbon receptor nuclear translocator-like protein 1 (ARNTL or BMAL1), which form a heterodimer and is translocated to the nucleus, thus promoting the transcription of the downstream targets, such as PERs and CRYs [4] . In the negative limb of TTFL, the protein products of PERs and CRYs form a heterodimer, which is translocated to the nucleus and subsequently dissociates the CLOCK: BMAL1 dimer from the promoter region of their own genes, thus suppressing their gene expression [5] . Disruption of the circadian clock is associated with many diseases, such as obesity, diabetes, heart diseases, and cancer [6, 7] . Therefore, identifying the regulatory factors of the core clock proteins may help us understand the molecular mechanisms underlying dysregulation of the circadian clock and a variety of diseases.
The core proteins governing the circadian clock can be modulated not only at the transcriptional level but also at the post-translational level [8] [9] [10] . Ubiquitination is one of the major post-translational modifications that regulates the stability of many core clock proteins and thus affects their biological functions [11] . In the ubiquitin-proteasome system (UPS), E1 activating enzymes, E2 conjugating enzymes, and E3 ligases work sequentially to conjugate ubiquitin to the lysine (or less frequently other) residues of their substrates [11] . Among these enzymes, E3 ligases play critical roles in recognizing the substrates targeted for the modification and in determining the types of ubiquitination, such as monoubiquitination or polyubiquitination, therefore differentially regulating the biological functions of the substrates. Several E3 ligases have been shown to modulate the ubiquitination and degradation of core circadian proteins, mainly in the negative limb of the TTFL. F-box/ LRR-repeat protein 3 (FBXL3) and FBXL21 function as substrate receptors to form Skp-Cullin-F box (SCF) E3 ligases, which ubiquitinate cryptochrome (CRY) and period (PER) proteins with different types of polyubiquitin chains and thus differentially regulate the degradation and stability of CRY proteins, resulting in the opposite effect on circadian period [12] [13] [14] . The cullin-4 RING E3 ligase containing cdt10-dependent transcript 2 as a substrate receptor targets CRY1 for ubiquitination and degradation, leading to the reduced amplitude of the circadian rhythm [15] . Recently, multiple E3 ligases have also been shown to modulate the ubiquitination of other components of the circadian clock, such as REV-ERBa, causing its degradation and thus affecting the circadian clock [16] [17] [18] .
In contrast to the regulation of proteins in the negative limb of the TTFL, the ubiquitination of CLOCK and BMAL1 in the positive limb of TTFL has not been extensively studied. It is known that proteasomal inhibition accumulates CLOCK and BMAL1 proteins by hampering their normal degradation [19] , indicating that they are possibly modulated by the UPS. In fact, the ubiquitin-protein ligase E3A (UBE3A), the Angelman syndrome protein, promotes BMAL1 ubiquitination and its knockdown leads to the extended period and reduced amplitude of the circadian clock [20] . In the UPS, the E1s, E2s, and E3s are entwined to form a complicated regulatory network [21] . An E3 ligase can ubiquitinate multiple substrates and a substrate could also be ubiquitinated by multiple E3 ligases [22] . This phenomenon also exists for several circadian proteins, such as CRY [12] [13] [14] and REV-ERBa [16] [17] [18] . However, it is not clear whether there are other E3 ligases modulating BMAL1 ubiquitination and whether their regulation on BMAL1 ubiquitination affects its transcriptional activity or other biological functions. In addition, BMAL1 is not only a master regulator of the circadian clock but also plays important roles in the regulation of protein translation [23] , cell senescence [24] , and growth of acute myeloid leukemia [25] . Therefore, identifying its upstream regulators may link them with the broad spectrum of biological processes and discover their potential roles in the development of diseases associated with circadian rhythm dysfunction and may promote the development of therapeutic approaches for disease intervention.
In this work, we use protein interaction network analysis (PINA) and biochemical approaches to demonstrate that TNF receptor-associated factor 2 (TRAF2) as an E3 ligase modulates the ubiquitination and stability of BMAL1, thus affecting its transcriptional activity and biological functions, such as circadian clock in cells. We also find that TRAF2 interacts with BMAL1 in a domain different from its conventional substrate recognition domain. This work extends the regulatory functions of TRAF2 as an E3 ligase through protein ubiquitination and degradation.
Results

Ubiquitin E3 ligase TRAF2 reduces BMAL1 protein level
To explore the potential regulators for BMAL1, we searched the literature and analyzed the data from PINA database [26] for E3 ligases which might interact with core clock proteins BMAL1 and CRY1. We found that several E3 ligases or their components, such as CBL-B, cullin-1, F-box/WD repeating-containing protein 1A (BTRC or b-TrCP), FBXL3, TRAF2, and UBE3A, have been reported to interact with either BMAL1 or CRY1 (Fig. 1A) , suggesting that these E3s or subunits might possibly regulate the ubiquitination and the stability of these two proteins. Previous publications have demonstrated that b-TrCP, FBXL3, and UBE3A modulate the ubiquitination of the core clock proteins and circadian behavior [12, 20, [27] [28] [29] [30] [31] . Cullin-1 is the scaffold protein in the SCF E3 ligase complexes and regulates the ubiquitination of circadian proteins with substrate receptors, such as FBXL3 [12, 29] and bTrCP [27, 30, 31] . Therefore, we sought to examine whether TRAF2 also affects the protein level of circadian proteins. Since TRAF2 was reported to interact with CRY1 in a high-throughput yeast two-hybrid screening [32] , we first examined the effect of TRAF2 on CRY1 protein level using a gradient transfection of TRAF2 in HEK293T cells. Immunoblotting of cell lysates showed that CRY1 protein level was barely altered by TRAF2 (Fig. 1B) . This suggests that the interaction between CRY1 and TRAF2 may be indirect or this interaction does not lead to the degradation of CRY1, at least, under our experimental conditions.
Since the deubiquitinating enzyme USP2 interacts with and modulates the deubiquitination and stability of BMAL1, PER1, and CRY1 [33] [34] [35] [36] , we thought that TRAF2 might also affect multiple core clock proteins, such as BMAL1. In fact, PINA and literature analysis showed that BMAL1 could interact with CRY1 (Fig. 1C ), suggesting the possible connection between BMAL1 and TRAF2. To examine the effect of TRAF2 on BMAL1 protein level, we transfected a control or Myc-TRAF2 plasmid into HEK293T cells and immunoblotted of endogenous BMAL1. The result demonstrated that TRAF2 expression indeed reduced the BMAL1 protein level (Fig. 1D ). Immunoblotting results clearly demonstrated that TRAF2 was coimmunoprecipitated with FLAG-BMAL1 ( Fig. 2A) and FLAG-BMAL1 was also detected in the Strep-TRAF2 pulldown (Fig. 2B) . To further examine whether the endogenous proteins interact with each other, we immunoprecipitated BMAL1 from the cell lysate obtained from a neuroblastoma N2a cell line. Immunoblotting of TRAF2 detected an apparent band in the BMAL1 immunoprecipitate but not in the mock IgG immunoprecipitate (Fig. 2C ). Taken together, these results clearly demonstrate the interaction between BMAL1 and TRAF2. Next, we asked whether TRAF2 interacts with BMAL1 at its conventional substrate recognition domain, the TRAF domain. To test this, we constructed several TRAF2 truncates, including DRING, N terminus (N-term), C terminus (C-term, i.e., the TRAF domain), and zinc finger domains, with Myctags at their N termini (Fig. 2D) . We then cotransfected FLAG-BMAL1 with pcDNA3.1, full-length or truncated TRAF2 plasmids into HEK293T cells and immunoprecipitated FLAG-BMAL1. Immunoblotting results showed that the full length TRAF2 and truncates were expressed at a similar level and BMAL1 coimmunoprecipitated the full-length TRAF2, DRING, N terminus, and zinc finger truncation mutants but not the C-terminal truncate (C-term) (Fig. 2E ). To further verify this result, we carried out a reverse immunoprecipitation and the western blotting analysis showed that the full length, DRING, N terminus, and zinc finger domain but not the C-terminal domain of TRAF2 immunoprecipitated FLAG-BMAL1 (Fig. 2F ). These data demonstrate that the zinc finger domain, not the conventional substrate recognition TRAF domain, in TRAF2 is responsible for the interaction between TRAF2 and BMAL1.
TRAF2-mediated reduction of BMAL1 protein requires its catalytic RING domain
To further validate the reduction of BMAL1 protein level by TRAF2, we transfected a gradient amount of TRAF2 plasmid into HEK293T cells. Immunoblotting of cell lysates showed that the endogenous BMAL1 was reduced by TRAF2 in a dose-dependent manner. This reduction was statistically significant when TRAF2 was expressed to a relative high level (Fig. 3A) .
Next, we asked whether the reduction of BMAL1 by TRAF2 is modulated by its E3 ligase activity. We expressed pcDNA3.1, the full-length, or DRING TRAF2 in HEK293T cells and prepared the cell lysates. Immunoblotting of the endogenous BMAL1 showed that the reduction of BMAL1 protein level was only observed when the full length TRAF2 but not the DRING TRAF2 mutant was expressed (Fig. 3B ). This suggests that the reduction of BMAL1 by TRAF2 depends on its E3 ligase activity since the DRING truncate can still interact with BMAL1 ( Fig. 2D-F ). This result also demonstrates that both the RING domain and the zinc finger domain in TRAF2 are required to decrease the BMAL1 protein level.
To rule out the possible cell-type specific effect, we used three different sets of Traf2 siRNAs to knock down Traf2 in mouse neuroblastoma N2a cells. Three sets of Traf2 siRNAs had similar knockdown efficiency for Traf2 and the endogenous BMAL1 protein level was steadily increased (Fig. 3C ). This result further supports the regulation of BMAL1 by TRAF2 and this regulation is most probably not cell-type specific or not artificially induced by TRAF2 overexpression.
TRAF2 promotes BMAL1 ubiquitination and degradation
To further explore the mechanism by which TRAF2 reduces BMAL1 protein level, we first tested the effect of TRAF2 on the BMAL1 degradation rate. HEK293T cells cotransfected with FLAG-BMAL1 and a control or SF-TRAF2 plasmid were treated with a protein Immunoblotting of cell lysates from different CHX treatment time showed that the BMAL1 degradation rate was dramatically increased when TRAF2 was expressed and the half-life of BMAL1 was reduced from 10 h to 4 h upon TRAF2 expression (Fig. 4A) .
Next, we examined whether the effect of TRAF2 on BMAL1 was modulated by the proteasome activity. To do so, we treated cells with a proteasome inhibitor MG132 in the absence or presence of exogenously expressed TRAF2 and immunoblotted the cell lysates. In the absence of MG132, BMAL1 was significantly reduced upon TRAF2 expression (Fig. 4B, lanes 1 and  2) , consistent with the previous discovery ( Figs 1D  and 3A,B) . However, in the presence of MG132, BMAL1 protein level was no longer altered by TRAF2 (Fig. 4B, lanes 3 and 4) and its protein level was higher than that in the absence of MG132 (Fig. 4B , bottom panel). Taken together, these data clearly demonstrate that BMAL1 is most probably downregulated by TRAF2 through the UPS.
To further examine whether TRAF2 regulates BMAL1 ubiquitination, we coexpressed FLAG-BMAL1 and HA-Ub along with pcDNA3.1, TRAF2, or the DRING mutant in HEK293T cells and then treated the cells with DMSO or MG132. Cell lysates were immunoprecipitated with FLAG M2 affinity gel and immunoblotted for ubiquitin and BMAL1 (FLAG). The result clearly showed that BMAL1 ubiquitination was markedly increased upon expressing the full length TRAF2 but not the DRING mutant (Fig. 4C ). This result further demonstrates that TRAF2 decreases BMAL1 protein level by promoting its ubiquitination and degradation. Means AE SEMs were depicted and P-value was calculated using Student's t-test against the sample transfected with pcDNA3.1. *P < 0.05; ns, not significant. (B) The TRAF2 RING domain is responsible for the downregulation of endogenous BMAL1. HEK293T cells were transfected with pcDNA3.1, full-length TRAF2, or DRING TRAF2 plasmid. Cells were lysed 48 h after transfection and cell lysates were immunoblotted. Quantification was performed as described in (A). **P < 0.01; ***P < 0.001; ns, not significant. (C) Traf2 knockdown increases BMAL1 protein level. N2a cells were transfected with control siRNAs or three different sets of Traf2 siRNAs. Cells were lysed 48 h after transfection and cell lysates were immunoblotted. Quantification was performed as described in (A). *P < 0.05.
TRAF2 attenuates the BMAL1 transcriptional activity
BMAL1 is a transcription factor that activates the expression of E-box genes and then modulates a variety of biological processes. Since TRAF2 reduces BMAL1 protein level, we sought to examine whether TRAF2 also alters BMAL1 transcriptional activity. First, we used a luciferase reporter assay to test this possibility. We transfected pcDNA3.1, FLAG-TRAF2, FLAG-BMAL1, or FLAG-BMAL1 and FLAG-TRAF2 plasmids along with PER1 E-box firefly luciferase reporter plasmid, renilla luciferase control reporter vector, and HA-CLOCK plasmid into HEK293T cells, and then measured the luciferase signals with the dual-luciferase reporter assay system. As predicted, BMAL1 expression markedly increased the relative Ebox luciferase signal, indicating the increase of BMAL1 transcriptional activity. However, when TRAF2 was expressed, the relative luciferase signal was significantly attenuated, suggesting the reduction of BMAL1 transcriptional activity (Fig. 5A) . Here, the slight reduction of luciferase activity upon TRAF2 expression in the absence of BMAL1 expression (Fig. 5A, lane 3) was presumably caused by the reduction of endogenous BMAL1 protein. To rule out the possible nonspecific effect, we performed the above luciferase reporter assay with a BMAL1 RORE-box luciferase plasmid. Here, the positive control expressing FLAG-RORa significantly increased the relative luciferase signal but further expression of FLAG-TRAF2 had no additional effect (Fig. 5B) . These results are consistent with the fact that TRAF2 downregulates exogenously expressed BMAL1 but not RORa, demonstrated in the immunoblotting images below the bar graph (Fig. 5B) . To further validate this result, we performed a qPCR experiment for BMAL1 and two BMAL1 regulated genes, PER1 and NR1D1 (REV-ERBa), after TRAF2 transfection. Indeed, the ) for the indicated time and cell lysates were used for immunoblotting analysis. Experiments were carried out triplicates and P-values were calculated using two-way ANOVA. ***P < 0.001. (B) Proteasomal inhibition rescues the BMAL1 protein level reduced by TRAF2. HEK293T cells were transfected with pcDNA3.1 or Myc-TRAF2 plasmids for 48 h and then treated with MG132 (10 lM) for 12 h. Cell lysates were immunoblotted. P-values were calculated for data obtained from four biological replicates using Student's t-test. **P < 0.01; ns, not significant. (C) TRAF2 enhances BMAL1 ubiquitination. HEK293T cells were transfected with FLAG-BMAL1 and HA-Ub plasmids for 6 h and then split. At 24 h after the first transfection, cells were further transfected with pcDNA3.1, TRAF2, or DRING plasmid. At 36 h after the second transfection, cells were treated with DMSO or MG132 (10 lM) for 12 h and BMAL1 was immunoprecipitated with FLAG M2 affinity gel. Cell lysates and immunoprecipitates were immunoblotted with the indicated antibodies. The experiment was repeated twice and similar results were obtained. reduces PER1 E-box luciferase signal. pcDNA3.1, FLAG-TRAF2, FLAG-BMAL1, or FLAG-TRAF2 and FLAG-BMAL1 were cotransfected with HA-CLOCK, PER1 E-box firefly luciferase reporter, and renilla luciferase reporter plasmids into HEK293T cells. pGL3 was used as a negative control. Cells were lysed 36 h after transfection and cell lysates were used to measure firefly luciferase and renilla luciferase signals. The relative firefly luciferase signal was obtained by normalizing to the renilla luciferase signal. Means AE SEMs were plotted for data from three technical replicates. P-values were calculated using Student's t-test against the data obtained from the pcDNA3.1 plasmid or as indicated. *P < 0.05; **P < 0.01; ***P < 0.001. Western blotting images under the bar graph indicated protein expression. The experiment was repeated twice and similar results were obtained. (B) TRAF2 does not affect BMAL1 RORE-box luciferase signal. The experiments were done as described in (A) except that the PER1 E-box firefly luciferase reporter plasmid was replaced with BMAL1 RORE-box reporter plasmid and FLAG-BMAL1 was replaced with FLAG-RORa. ***P < 0.001; ns, not significant, compared against the data obtained from the pcDNA3.1 plasmid or as indicated. The experiment was repeated twice and similar results were obtained. (C) TRAF2 reduces BMAL1 transcriptional activity. pcDNA3.1 or TRAF2 plasmid was transfected into HEK293T cells along with the HA-CLOCK plasmid. Total RNAs were extracted 48 h after transfection and the first strand cDNAs were synthesized and the relative mRNA level was measured with qPCR. P-values were calculated using Student's t-test against the pcDNA3.1 transfected samples. *P < 0.05; **P < 0.01; ns, not significant. Immunoblotting were used to indicate the protein expression. The experiment was repeated triplicates. result showed that BMAL1 mRNA level was not affected by TRAF2 expression (Fig. 5C ), which supported the idea that the reduction of BMAL1 protein level by TRAF2 was through the UPS but not through the alteration of BMAL1 mRNA level. However, the PER1 and NR1D1 mRNAs were significantly reduced upon TRAF2 expression, presumably due to the reduction of BMAL1 protein level (Fig. 5C ). Taken together, these results demonstrate that the reduction of BMAL1 by TRAF2 attenuates its transcriptional activity.
TRAF2 modulates the maximal Per1 mRNA level of the circadian clock in N2a cells
Above results clearly demonstrated that TRAF2 reduced BMAL1 protein level through enhancing its ubiquitination and degradation and thus attenuated its transcriptional activity. Survey of Traf2 mRNA level in the circadian database CircaDB [37] found that Traf2 mRNA had an oscillation behavior in mouse heart and kidney tissues with the P-values of less than 0.05 (Fig. 6A ), indicating that this E3 ligase might affect the circadian rhythm because genes regulating circadian behavior also exhibit circadian oscillation.
To test whether TRAF2 affects the circadian clock, we transfected the control or Traf2 siRNAs into N2a cells and confirmed the reduction of TRAF2 and the increase of BMAL1 protein level (Fig. 6B) . Then, we measured the Per1 mRNA level at different time points after fetal equine serum (FES) treatment of the transfected cells. The relative Per1 mRNA level exhibited a pronounced oscillation after serum treatment and the amplitude of this oscillation was increased upon Traf2 knockdown (Fig. 6C) . Detailed inspection found that the maximal Per1 mRNA level was increased by about 35% and the relative Per1 mRNA level at 28 h after FES treatment was increased by about 125% (Fig. 6D) . Calculation of the period and phase of the oscillator using JTK_CYCLE [38] did not detect significant changes upon Traf2 knockdown. qPCR was performed triplicates and P-value was calculated using two-way ANOVA. The experiments were repeated twice and similar results were obtained. (D) The relative abundance of Per1 mRNA at 16 and 28 h after 50% FES treatment of N2a cells transfected with control or Traf2 siRNAs. P-value was calculated using Student's t-test against the control siRNAs. **P < 0.01; ns, not significant.
Discussion
Ubiquitination and proteasomal degradation play important roles in modulating protein levels and altering their biological functions. In this work, we found a novel E3 ligase TRAF2 that interacted with the core clock protein BMAL1 and modulated its ubiquitination, stability, and transcriptional activity. Circadian rhythm measurement further revealed that TRAF2 knockdown increased the maximal Per1 mRNA expression of the circadian clock in a cell line. These results evidently demonstrated that TRAF2 regulated the circadian function through promoting BMAL1 ubiquitination and degradation. This is also consistent with the oscillation of Traf2 mRNA in animal tissues although a recent proteomic study on the oscillation of phosphoproteins in mouse liver did not detect TRAF2 phosphorylation, presumably due to the low abundance of its phosphorylation level [39] . Our experiments detected the alteration of Per1 mRNA level and its oscillation upon Traf2 knockdown in N2a cells although this effect is not very strong. In addition, we did not detect significant change in the oscillation of other BMAL1 downstream genes upon Traf2 knockdown. Several possible reasons may result in this phenomenon. First, these genes may be expressed at relatively low levels in N2a cells. Second, the knockdown of Traf2 by small interfering RNA may not be highly efficient. Third, the effect of TRAF2 on these genes may not be strong enough to affect the overall oscillation of these genes. Fourth, other regulatory factors may compensate the effect of TRAF2 on the expression of these genes.
Previous studies demonstrated that TRAF2 could promote the formation of both K48-and K63-linked polyubiquitin chains [40, 41] . Although we did not specifically determine the type of polyubiquitin chains on BMAL1, the fact that TRAF2 promotes BMAL1 ubiquitination and reduces its stability suggests that TRAF2 most likely modulates the formation of K48-linked polyubiquitin chain. This is in concert with the fact that the RING domain in TRAF2 is required to reduce BMAL1 protein level and that BMAL1 mRNA level is not affected by TRAF2 expression or knockdown. Our study further found that BMAL1 interacted with TRAF2 in its zinc finger domain instead of its conventional substrate recognition TRAF domain. This suggests that different substrate recognition domains in TRAF2 might have distinct regulatory functions on its substrates. Further studies are required to test this conjecture.
A previous publication found that UBE3A affected the circadian behavior through modulating BMAL1 ubiquitination and stability [20] . That study revealed that Ube3a knockdown extended the period and reduced the amplitude of the circadian rhythm in Drosophila. Our experiments showed that TRAF2 altered the circadian amplitude but not the period in cells although both UBE3A and TRAF2 modulate the ubiquitination and stability of BMAL1. Multiple substrates, such as the activity-regulated cytoskeleton-associated protein Arc [42] , p53 [43] , and ubiquitin carboxyl-terminal hydrolase isozyme L5 [44] , were found to be ubiquitinated by UBE3A in neuronal or non-neuronal cells although not all of them were degraded by the proteasome after ubiquitination. In fact, p53 regulates Per2 mRNA level and p53-deficient mice have a shorter period, indicating its role in the regulation of circadian behavior [45] . Another UBE3A substrate Arc is also a light-inducible early gene in mouse suprachiasmatic nucleus and is involved in the light-induced phase-shift of the circadian clock [46] . Studies in the neuronal development discovered that UBE3A and its ubiquitin ligase activity were necessary for maintaining the plasticity in neocortical development [47] and Ube3a knockout mice exhibited impaired long-term potentiation [48] . These neuronal functions may also affect the circadian rhythm. It is highly possible that the regulation on the circadian behavior by UBE3A might act through multiple pathways. Although TRAF2 can promote the ubiquitination of caspase-8 for its deactivation in the apoptotic pathway [40] and is required for the formation of mixed polyubiquitin chains on mixed lineage kinase 3 [49] , no direct connection between these proteins and circadian behavior has been discovered.
Although there are a lot of studies on BMALl and TRAF2, no signaling pathway has been discovered to modulate BMAL1 protein level or biological function through TRAF2. However, TRAF2 is an E3 ligase and its activation can be modulated by its own ubiquitination [50] . Through its ubiquitination, TRAF2 can mediate the activation of NF-jB and thus the activation of inflammation induced by TNF-a [51] . It has also been reported that TNF-a modulates the BMAL1 mRNA expression or BMAL1 transcription activity through distinct mechanisms and in two opposite manners [52, 53] . These facts suggest that there might be some signaling pathways which bridge TRAF2 and BMAL1. It would be interesting to explore the pathways that regulate TRAF2 and thus BMAL1.
BMAL1 and TRAF2 are two differentially regulated proteins in multiple cancers, which might reflect their specific roles in cancer development. Previous studies show that TRAF2 is upregulated in multiple cancers, such as pancreatic cancer [54] and lung cancer [55] , and promotes the invasiveness of pancreatic cancer cells [54] . In contrast, BMAL1 is downregulated in pancreatic cancer [56] and its overexpression suppresses invasiveness in lung cancer cells [57] while its knockdown accelerates cell proliferation and promotes tumor growth in mice [58] . These results suggest that there might be a close connection between TRAF2 and BMAL1 in the regulation of cancer progression. Circadian rhythm might be their convergent point. A recent study found that elevated BMAL1 expression increased the sensitivity of tongue squamous cell carcinoma to a chemotherapeutic drug, paclitaxel. This discovery suggests that it might be possible to increase the efficiency of patient treatment by adjusting the time to take the drug [59] . It might also be useful to design therapeutic approaches that increase BMAL1 protein level by inhibiting E3 ligase activities to suppress cancer cell progression. . FLAG peptide (DYKDDDDK) was from ChinaPeptides (Hangzhou, Zhejiang, China), Strep-tactin agarose beads and desthiobiotin were from IBA Lifesciences (Goettingen, Germany), CHX was from Sigma, and MG132 was from Selleck (Houston, TX, USA).
Materials and methods
Materials
Plasmid construction
Total RNA was isolated from HEK293T cells with TRIzol reagent (Thermo Fisher, Waltham, MA, USA). First strand cDNA was synthesized with Revert Aid First Strand cDNA Synthesis kit (Thermo Fisher). Polymerase chain reaction (PCR) was conducted with TransStart FastPfu DNA polymerase (TransGen Biotech, Beijing, China) using following primers for TRAF2: 5 0 -CCCGGGCTGCAG GAATTCATGGCTGCAGCTAGCGTGACC-3 0 (forward) and 5 0 -GGATCTAAAGCACTCGAGTTAGAGCCCTGT CAGGTCCAC-3 0 (reverse). The PCR product was cloned to the pcDNA3.1 vector with pEASY-UniSeamless Cloning and Assembly kit (TransGen Biotech). The TRAF2 truncates were obtained from standard subcloning methods. FLAG-BMAL1, HA-CLOCK, pGL3, E-box and ROREbox luciferase reporter, and renilla luciferase reporter plasmids were kindly provided by Ying Xu at Soochow University. All plasmids were verified by Sanger sequencing. HAUb plasmid was obtained from a previous study [60] .
Cell culture and plasmid transfection HEK293T cells were cultured in high-glucose Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY, USA) supplemented with 10% FBS (PAN Biotech, Aidenbach, Germany, and Lonsera, Shanghai, China), 100 units/mL penicillin, and 100 lg/mL streptomycin (Gibco). N2a cells were cultured in Opti-MEM (Gibco) reduced serum medium supplemented with 10% FBS along with penicillin and streptomycin. Cells were cultured in 37°C and 5% CO 2 humidified incubator. Plasmids were transfected into HEK293T cells using polyethyleneimine (Sigma) transfection reagents. pcDNA3.1 was used to balance the total amount of transfected plasmids.
siRNA knockdown 
Western blotting analysis
Cells were washed with ice-cold PBS and lysed on ice with modified RIPA buffer (50 mM Tris/HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA) containing freshly prepared protease inhibitor cocktail (Roche, Basel, Switzerland). Western blotting analysis was carried out according to a previously published method [61] . Proteins from cell lysates (~20 lg) were separated by SDS/ PAGE and transferred to poly(vinylidene difluoride) membranes. Membranes were blocked with 5% nonfat milk, incubated with indicated primary and secondary antibodies, and washed three times with TBST (TBS with 0.1% Tween 20) after incubating with each antibody. Immobilon Western chemiluminescent HRP substrates were used to detect protein bands and the chemiluminescent signal was recorded in a Bio-Rad ChemiDoc or Tanon 5200 imaging system. The relative intensity was quantified and normalized to the loading control. Statistics were carried out for three or four biological replicates to obtain P-values using Student's t-test or two-way analysis of variance (ANOVA).
Cycloheximide (CHX) chase experiment
HEK293T cells were transfected with the control or FLAG-TRAF2 plasmid along with FLAG-BMAL1 plasmid. Cells were equally split to each well of six-well plates and cultured in the growth medium. At 48 h post-transfection, cells were treated with CHX (200 lg/mL) for the indicated time, washed with ice-cold PBS, and lysed in the modified RIPA buffer containing freshly added protease inhibitor cocktail with brief sonication for immunoblotting analysis.
Affinity purification
Cell lysates were incubated with prewashed anti-FLAG M2 affinity gel at 4°C overnight. The FLAG-tagged BMAL1 and its interacting proteins were eluted with 200 lgÁmL À1 FLAG peptides after extensive washing with TBST. For the Strep-tactin purification, cell lysates expressing control or Strep-TRAF2 were incubated with Strep-tactin agarose beads and eluted with 5 mM desthiobiotin after extensive washing as described previously [62] . Myc-tagged TRAF2 and its truncation mutants were purified using anti-Myc magnetic beads. Briefly, cell lysate was incubated with the prewashed anti-Myc magnetic beads at 4°C overnight. The magnetic beads were then washed six times with RIPA buffer containing 0.3 M NaCl and again six times with RIPA buffer. Proteins were eluted with 80 lL SDS sample loading buffer by heating at 98°C for 10 min.
Luciferase reporter assay pcDNA3.1, FLAG-TRAF2, FLAG-BMAL1, or FLAG-TRAF2 and FLAG-BMAL1 plasmids along with PER1 Ebox or BMAL1 RORE-box firefly luciferase reporter plasmid [63] , renilla luciferase control reporter vector, and HA-CLOCK plasmid were transfected into HEK293T cells. Cells were washed and lysed in passive lysis buffer 36 h after transfection. The luciferase signals were measured with the dualluciferase reporter assay system (Promega, Madison, WI, USA). The signal from firefly luciferase reporter gene was normalized to that of the renilla luciferase gene. The data obtained from the pcDNA3.1 control samples were used for normalization.
Real-time quantitative PCR (qPCR) measurement 
Circadian rhythm measurement
N2a cells were transfected with 100 pmol control or Traf2 siRNAs using lipofectamine 2000 transfection reagent in 6-cm plates. At 12 h post-transfection, cells were split to sixwell plates and at 24 h post-transfection, culture medium was changed to serum shock medium (Opti-MEM supplemented with 50% FES; Gibco). This time was set to 0 h. After 16 h, serum shock medium was replaced with Opti-MEM containing 0.5% FBS and cells were harvested for the first time point. Cells were then collected every 4 h. Total RNA was extracted, the first strand cDNA was synthesized, and qPCR was carried out to measure the relative amount of Per1 mRNA at different time points. The data were normalized to the first time point of the control or the experimental samples, respectively.
